REG-Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
Oculis announced that new biomarker data from the Phase 2 ACUITY trial of Privosegtor in acute optic neuritis will be presented in a late-breaking session at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto. The analyses, to be presented by principal investigator Professor Céline Louapre on October 22, evaluate plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation.
Key figures
- Drug Name
- Privosegtor
- Phase Of Trial
- Phase 2
- Rd day
- December 8, 2026
- Presentation id
- P1507
- Presentation datetime
- October 22, 2026, 4:30-6:30 p.m. EDT
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.